In contrast to RUNX1 and RUNX3, whose mutations are closely linked to the promotion of leukemia and GC, respectively [28,29], the initial studies suggest that RUNX2 acts as a master regulator of osteoblast differentiation and bone development. Here, RUNX3 is linked to leukemia.